Vimarsana
Biggest News Aggregation in the World

Page 2 - Serial Studies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Serial Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Serial Studies Today - Breaking & Trending Today

I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19 - Vimarsana News

I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19

/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been...

I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19 - Vimarsana News

I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19

/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been...

I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19 - Vimarsana News

I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients - Vimarsana News

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.